Skip to main content
Fig. 1 | Hereditary Cancer in Clinical Practice

Fig. 1

From: Cytotoxic and targeted therapy for hereditary cancers

Fig. 1

Selective sensitivity of BRCA1/2-associated tumors to genotoxic agents. Normal cells from BRCA1/2 mutation carriers retain full capacity of genome maintenance mechanisms (left). Development of tumors in these patients involves somatic inactivation of the remaining BRCA1/2 allele, therefore malignant cells are unable to cope with double-strand DNA breaks (right)

Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287